[Expression of markers of immunocompetent cells, cytokine level, and L-arginine metabolism in complex extremely high frequency and interferon therapy of inflammatory diseases in women of highlands].

Article

Author: Uzdenova, Z Kh ; Doloman, L B ; Kamenetskaia, O V ; Kotsiuruba, A V ; Krivokhatskaia, L D ; Mandziuk, Ia P ; Bichekueva, F Kh ; Taradiĭ, N N ; Bagdasarova, I V ; Volkova, L N

Chronic inflammatory gynecological diseases (CIGD) in highlanders (2,100-2,200 m a.s.l.) are accompanied with the following changes in immunoregulatory parameters: strengthening in the expression of CD3+ (TCR), CD4+ (T-helpers), CD16+ (NK-cells), CD25+ (activated IL-2R), increase in CD4+/CD8+ ratio, levels of circulating cytokines--alpha-, beta-, gamma-interferon (IFN) and alpha-, beta-tumor necrotizing factor (TNF), strengthening in immune adhesion of thrombocytes (IAT), and inhibition of the oxidative metabolic way of L-arginine with redistribution of the main metabolites formed via its non-oxidative way. Complex extremely high frequency (EHF) therapy and interferon (with Laferon) therapy of CIGD normalized expression of the differentiated and functional CD-markers of immunocompetent cells (ICC), CD4+/CD8+ ratio, increased expression of CD8+, decreased IAT and levels of circulating cytokines (IFN, TNF), changed L-arginine metabolism with activation of the oxidative way. Full-value of the population signs of immune stabilization due to the treatment was complemented with increase in the ICC functional parameters--markers of mitochondrial, lysosomal and mitotic activity. We first demonstrated a high effectiveness of complex use of EHF and Laferon as an immunocorrective therapy of CIGD in highlanders.

01 Apr 2002·Klinichna khirurhiia

[The application of laferon in a combined therapy of purulent cholangitis].

Article

Author: Serdiuk, V P ; Khomiak, I V ; Todurov, I M ; Kopchak, V M ; Stasenko, A A ; Gusev, A V ; Dronov, A I

Results of treatment of 160 patients, operated on for nontumoral biliary ducts impassibility, complicated by purulent cholangitis, were analyzed. In 60 patients intraoperatively and after the operation in complex of treatment laferon solution was injected into biliary ducts in dosage 500,000--1 million IU a day, permitting to reduce the frequency of the postoperative complications occurrence from 62.2 to 36% and of postoperative mortality--from 13 to 6%. Regional immune therapy using laferon stimulates the factors of organism inflammatory reaction and hepatocytes functional state restoration.

01 Jan 2002·Likars'ka sprava

[Treatment of dystrophy, dysplasia and initial stages of vulvar carcinoma in virus infections].

Article

Author: Tkachuk, T Ie

Overall sixty-seven patients with distrophy, dysplasia and valvular carcinoma presenting with human papilloma virus- and herpes simplex-2 virus infections underwent a complex treatment intended for background, precancerous affections of the vulva and for valvular carcinoma, involving the use of antiviral drug preparations laferon, zovirax, lovir (both on the systemic and local basis), and an immunomodulator (decaris). Efficacy of the above treatment option has been shown to be 98.5%.

100 Deals associated with Interferon alpha-2b biosimilar(Pharmbiotek)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bladder Cancer	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Bone Marrow Neoplasms	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Breast Cancer	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Chlamydia Infections	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Hairy Cell Leukemia	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Hepatitis B	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Herpesviridae Infections	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Human Papillomavirus Infection	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Kaposi Sarcoma	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Melanoma	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Multiple Sclerosis	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Non-Hodgkin Lymphoma	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Ovarian Cancer	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Philadelphia chromosome positive chronic myelogenous leukemia	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Renal Cell Carcinoma	UA	PharmBiotek Research and Production LLC.	01 Jan 2004
Sepsis	UA	PharmBiotek Research and Production LLC.	01 Jan 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis